April 2013 Newsletter

TARIS® Announces Dosing of First Patient in Second Phase 2 Clinical Study of LiRIS® in Interstitial Cystitis

Taris dosed the first patient in its second Phase 2 clinical study with LiRIS. For patients with Interstitial Cystitis, LiRIS will allow for continuous lidocaine delivery directly to the bladder over an extended period. Read more.

3D Ear Scanning: Is a Customized Ear Bud Revolution on the Horizon?

The Lantos ear scanning technology has a lot of practical uses and the video in this article demonstrates exactly how it works. Read more.

FIREFLY BIOWORKS IN THE NEWS

Daniel Pregibon is an MIT alum and Deshpande grantee whose company, Firefly BioWorks, provides rapid, cost-effective microRNA profiling which is beneficial for diagnosing diseases. Read more.

The Firefly Frontiers Grant, for scientists interested in profiling large numbers of samples over multiple microRNA targets, was awarded to twelve teams totaling $120,000. Read more.

DESHPANDE SPINOUTS SECURE ADDITIONAL FUNDING

QD Vision closed a $20M round of funding this month that will be used to support long term growth and expand high volume production capacity. Read more.

TARIS Biomedical raised an additional $12.5M from existing investors to continue developing innovative, targeted therapies to treat bladder disease. Read more.